Lexeo Therapeutics, Inc.
LXEO
$4.84
-$0.12-2.42%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 21.17% | -3.13% | |||
| Gross Profit | -21.17% | 3.13% | |||
| SG&A Expenses | 35.64% | -4.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 25.46% | -3.39% | |||
| Operating Income | -25.46% | 3.39% | |||
| Income Before Tax | -28.08% | 3.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -28.08% | 3.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.08% | 3.46% | |||
| EBIT | -25.46% | 3.39% | |||
| EBITDA | -25.64% | 3.41% | |||
| EPS Basic | -21.42% | 9.20% | |||
| Normalized Basic EPS | -21.12% | 9.00% | |||
| EPS Diluted | -21.42% | 9.20% | |||
| Normalized Diluted EPS | -21.12% | 9.00% | |||
| Average Basic Shares Outstanding | 5.47% | 6.32% | |||
| Average Diluted Shares Outstanding | 5.47% | 6.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||